Montreal, QC, CA, and Charlotte, NC, [May 13, 2019] – Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the launch of a disease

MONTREAL and CHARLOTTE, N.C. , May 13, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the closing of its

MONTREAL and CHARLOTTE, N.C. , May 8, 2019 /PRNewswire/ --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its

MONTREAL and CHARLOTTE, N.C. , April 16, 2019 /PRNewswire/ -- Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular conditions, today announced the appointment of Paul Edick as Chairman of its Board of Directors.

Montreal, QC, CA, and Charlotte, NC, April 4, 2019 – Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular indications, today announced the appointment of Michael Tomsicek to its Board of Directors. Mr.